Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Curcumin  COVID-19 treatment studies for Curcumin  C19 studies: Curcumin  Curcumin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Recovery time 11% Improvement Relative Risk Fever 11% Congestion 20% Sore throat 20% Cough 14% Dyspnea 15% Pain 8% Fatigue 17% Headache 17% Chills 18% Diarrhea 25% Vomiting 18% Smell 17% Taste 17% c19early.org/t Chitre et al. CTRI/2020/09/027817 Curcumin RCT EARLY Favors curcumin Favors control
Phase III randomized clinical trial of BV-4051, an Ayurvedic polyherbal formulation in moderate SARS-CoV-2 infections and its impact on inflammatory biomarkers
Chitre et al., Phytotherapy Research, doi:10.1002/ptr.7683, CTRI/2020/09/027817
Chitre et al., Phase III randomized clinical trial of BV-4051, an Ayurvedic polyherbal formulation in moderate SARS-CoV-2.., Phytotherapy Research, doi:10.1002/ptr.7683, CTRI/2020/09/027817
Nov 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 208 moderate COVID-19 patients in India, 103 treated with a combination of turmeric, ashwagandha, boswellia, and ginger, showing improved recovery with treatment. The dose of curcumin is unknown and bioavailability may be poor.
recovery time, 11.3% lower, relative time 0.89, p = 0.04, treatment 89, control 86.
fever, 11.0% lower, RR 0.89, p = 0.03, treatment 70 of 89 (78.7%), control 76 of 86 (88.4%), NNT 10, day 4.
congestion, 20.0% lower, RR 0.80, p = 0.05, treatment 89, control 86, mid-recovery, day 7.
sore throat, 20.0% lower, RR 0.80, p = 0.09, treatment 89, control 86, mid-recovery, day 7.
cough, 14.3% lower, RR 0.86, p = 0.14, treatment 89, control 86, mid-recovery, day 7.
dyspnea, 15.4% lower, RR 0.85, p = 0.15, treatment 89, control 86, mid-recovery, day 7.
pain, 8.3% lower, RR 0.92, p = 0.41, treatment 89, control 86, mid-recovery, day 7.
fatigue, 16.7% lower, RR 0.83, p = 0.13, treatment 89, control 86, mid-recovery, day 7.
headache, 16.7% lower, RR 0.83, p = 0.12, treatment 89, control 86, mid-recovery, day 7.
chills, 18.2% lower, RR 0.82, p = 0.09, treatment 89, control 86, mid-recovery, day 7.
diarrhea, 25.0% lower, RR 0.75, p = 0.08, treatment 89, control 86, mid-recovery, day 7.
vomiting, 18.2% lower, RR 0.82, p = 0.07, treatment 89, control 86, mid-recovery, day 7.
smell, 16.7% lower, RR 0.83, p = 0.06, treatment 89, control 86, mid-recovery, day 7.
taste, 16.7% lower, RR 0.83, p = 0.14, treatment 89, control 86, mid-recovery, day 7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Chitre et al., 23 Nov 2022, Double Blind Randomized Controlled Trial, placebo-controlled, India, peer-reviewed, 8 authors, this trial uses multiple treatments in the treatment arm (combined with ashwagandha, boswellia, ginger) - results of individual treatments may vary, trial CTRI/2020/09/027817.
Contact: dchitre@bioved.com, snadkarni@bioved.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCurcuminAll
Abstract: Revised: 17 October 2022 Accepted: 25 October 2022 DOI: 10.1002/ptr.7683 RESEARCH ARTICLE Phase III randomized clinical trial of BV-4051, an Ayurvedic polyherbal formulation in moderate SARS-CoV-2 infections and its impact on inflammatory biomarkers Deepa Chitre 1 | Satej Nadkarni 1 Amol Gitte 4 | Prashant Rahate 5 1 Bioved Pharmaceuticals, Inc., San Jose, California, USA | | Namdev Jagtap 2 Sunetra Chaskar 6 | Rahul Tulle 3 | | Debendranath Dey 1 Abstract 2 Vishwaraj Hospital, Loni Kalbhor, Pune, India SARS-CoV-2 virus and its variants continue to be a challenge inspite of widespread 3 Vedant Hospital, Thane, Mumbai, India vaccination and preventive measures. We hypothesized an oral, safe polyherbal for- 4 Siddhivinayak Hospital, Thane, Mumbai, India 5 Seven Star Hospital, Nagpur, India 6 Bioved Pharmaceuticals Pvt. Ltd., Pune, India mulation with antiinflammatory properties may improve the clinical outcome of this disease. BV-4051, a formulation from four Ayurvedic plants namely Ashwagandha, Boswellia, Ginger and Turmeric was used for the treatment of hospitalized moderate Correspondence Deepa Chitre, Bioved Pharmaceuticals, Inc., 1929 O'Toole Way, San Jose, CA 95131, USA. Email: dchitre@bioved.com COVID-19 patients along with standard of care (SOC). Patients were randomly assigned to receive BV-4051 or placebo tablets for 14 days, at four sites in India during late 2020 to early 2021. Among 208 randomized subjects, 175 completed the study. In BV-4051 group the mean reduction in duration of illness (p = 0.036), alleviation and severity scores of several symptoms like fever, cough, smell, and taste disorders were statistically significant (p ≤ 0.05). A sub-set analysis of subjects treated with or without Remdesivir as SOC showed mean reduction in duration of illness in BV-4051 (p = 0.030), and severity scores (p ≤ 0.05). Mean difference in Interleukin-6 was statistically significant (p = 0.042) on BV-4051 without Remdesivir. BV-4051 may reduce duration of illness, symptoms severity, Interleukin-6, and prevent the incidence of COVID-19 complications. It may have an adjunctive effect with other SOC. Larger extensive clinical testing may give a better understanding of its effect. KEYWORDS ARTOVID-20®, Ayurveda, Covid-19, herbal, interleukin-6, Remdesivir 1 | I N T RO DU CT I O N certain populations in developed nations, the disease and its variants continue to cause significant morbidity, mortality, and economic Aggressive global vaccination efforts, widespread public healthcare impact (World Bank Report, 2022). measures, and a better understanding of treatment modalities provide Immune hyperactivation in COVID-19 is precipitated by a surge a significant improvement in the management of the SARS-CoV2 pan- of critical immune mediators including Tumor Necrosis Factor (TNF), demic. However, in many developing countries and also among Interferon-Gamma (IFN-γ), and Interleukin-6 (IL-6) that leads to respiratory failure, shock, and multi-organ dysfunction (Ablamunits & Clinical Trials Registry of India: CTRI/2020/09/027817. Lepsy, 2022; Herold et al., 2020; Mandel et al., 2020). There have This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. © 2022 Bioved Pharmaceuticals, Inc. Phytotherapy Research published by John Wiley & Sons Ltd. Phytotherapy Research...
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit